Contrasting Guided Therapeutics (GTHP) & Its Peers

Guided Therapeutics (OTCMKTS:GTHP) is one of 78 public companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare Guided Therapeutics to related businesses based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.

Institutional & Insider Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Guided Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ rivals have a beta of 0.85, suggesting that their average stock price is 15% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Guided Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	287	825	2136	109	2.62

As a group, “Electromedical equipment” companies have a potential upside of 2,878.06%. Given Guided Therapeutics’ rivals higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Guided Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-299.08%	-83.97%	-27.60%

Valuation & Earnings

This table compares Guided Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.33
Guided Therapeutics Competitors	$970.73 million	$79.50 million	9.84

Guided Therapeutics’ rivals have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Guided Therapeutics rivals beat Guided Therapeutics on 7 of the 10 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.